ArticleMolecular vision2010
Analysis of candidate genes for macular telangiectasia type 2.
Article in Molecular vision, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.Retina (Philadelphia, Pa.) · 2012Trial
- Clinical histopathology and pathogenesis of macular telangiectasia type 2.Progress in retinal and eye research · 2026Review
- Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025Review
- Risk and Resilience Variants in the Retinoic Acid Metabolic and Developmental Pathways Associated with Risk of FASD Outcomes.Biomolecules · 2024Article
- Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.International journal of retina and vitreous · 2023Review
- Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease.Scientific reports · 2020Article
- Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy.The New England journal of medicine · 2019Article
- Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy.Journal of biomedical optics · 2018Review
- Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.Ophthalmology. Retina · 2018Article
- CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.Retina (Philadelphia, Pa.) · 2018Observational
- Genome-wide analyses identify common variants associated with macular telangiectasia type 2.Nature genetics · 2017Article
- A new CRB1 rat mutation links Müller glial cells to retinal telangiectasia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Macular telangiectasia type 2.Progress in retinal and eye research · 2013Review
- Identification of a potential susceptibility locus for macular telangiectasia type 2.PloS one · 2012Article
- Characterization of the Retinal Phenotype Using Multimodal Imaging in Novel Compound Heterozygote Variants of CYP2U1.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo find the gene(s) responsible for macular telangiectasia type 2 (MacTel) by a candidate-gene screening approach.
methodsCandidate genes were selected based on the following criteria: those known to cause or be associated with diseases with phenotypes similar to MacTel, genes with known function in the retinal vasculature or macular pigment transport, genes that emerged from expression microarray data from mouse models designed to mimic MacTel phenotype characteristics, and genes expressed in the retina that are also related to diabetes or hypertension, which have increased prevalence in MacTel patients. Probands from eight families with at least two affected individuals were screened by direct sequencing of 27 candidate genes. Identified nonsynonymous variants were analyzed to determine whether they co-segregate with the disease in families. Allele frequencies were determined by TaqMan analysis of the large MacTel and control cohorts.
resultsWe identified 23 nonsynonymous variants in 27 candidate genes in at least one proband. Of these, eight were known single nucleotide polymorphisms (SNPs) with allele frequencies of >0.05; these variants were excluded from further analyses. Three previously unidentified missense variants, three missense variants with reported disease association, and five rare variants were analyzed for segregation and/or allele frequencies. No variant fulfilled the criteria of being causal for MacTel. A missense mutation, p.Pro33Ser in frizzled homolog (Drosophila) 4 (FZD4), previously suggested as a disease-causing variant in familial exudative vitreoretinopathy, was determined to be a rare benign polymorphism.
conclusionsWe have ruled out the exons and flanking intronic regions in 27 candidate genes as harboring causal mutations for MacTel.
Indexed as
Identifiers
21179236PMC3002960W2141847559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.